The Minnesota-run medtech giant announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved reimbursement for the system.

“This decision enables broader access to a therapy that has been shown to provide sustained reductions in blood pressure and improve outcomes for patients with hypertension,” Jason Weidman, SVP and president of Coronary & Renal Denervation at Medtronic, said in a news release. “We are proud to continue our 50-year legacy of serving patients in Japan through innovation and collaboration.”